<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAJ</journal-id>
<journal-id journal-id-type="hwp">sptaj</journal-id>
<journal-title>Therapeutic Advances in Chronic Disease</journal-title>
<issn pub-type="ppub">2040-6223</issn>
<issn pub-type="epub">2040-6231</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2040622312438935</article-id>
<article-id pub-id-type="publisher-id">10.1177_2040622312438935</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Hypertension in women: latest findings and clinical implications</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Gudmundsdottir</surname><given-names>Helga</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Høieggen</surname><given-names>Aud</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Stenehjem</surname><given-names>Aud</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Waldum</surname><given-names>Bård</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Os</surname><given-names>Ingrid</given-names></name>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2040622312438935">Professor Ingrid Os, MD, PhD Department of Nephrology, Oslo University Hospital Ullevål, Kirkeveien 166, N-0407 Oslo, Norway <email>ingrid.os@medisin.uio.no</email></corresp>
<corresp id="corresp2-2040622312438935">Helga Gudmundsdottir, MD, PhD Aud Høieggen, MD, PhD Aud Stenehjem, MD, PhD Department of Nephrology, Oslo University Hospital Ullevål, Oslo, Norway</corresp>
<corresp id="corresp3-2040622312438935">Bård Waldum, MD Department of Nephrology, Oslo University Hospital Ullevål, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>3</volume>
<issue>3</issue>
<fpage>137</fpage>
<lpage>146</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Cardiovascular disease claims more women’s lives than any other disease. Hypertension is an important risk factor for cardiovascular disease in women but is often underestimated and undiagnosed and there is an ongoing misperception that women are at a lower risk of cardiovascular disease than men. The attainment of clinical blood pressure goals can markedly reduce cardiovascular morbidity and mortality, yet approximately two-thirds of treated hypertensive women have uncontrolled blood pressure. Furthermore, there are special risk factors that are unique for women that needs acknowledgement in order to help prevent the great number of hypertension-related events in women. Guidelines for treatment of hypertension are similar for men and women. More studies on the interaction between gender and response to antihypertensive drugs would be of interest.</p>
</abstract>
<kwd-group>
<kwd>cardiovascular disease</kwd>
<kwd>hypertension</kwd>
<kwd>women</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2040622312438935" sec-type="intro">
<title>Introduction</title>
<p>Hypertension is a major risk factor for cardiovascular disease (CVD) and outcomes in women [<xref ref-type="bibr" rid="bibr96-2040622312438935">Smith <italic>et al.</italic> 2006</xref>]. Even though substantial progress has been made in the awareness, treatment, and prevention of CVD in women in the last decade, hypertension is often underestimated and undiagnosed [<xref ref-type="bibr" rid="bibr55-2040622312438935">Maas <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr64-2040622312438935">Mosca <italic>et al.</italic> 2011</xref>]. It is no longer true that CVD is a ‘man’s disease’. Heart disease is the leading cause of death in women in every major developed country and most emerging economies [<xref ref-type="bibr" rid="bibr29-2040622312438935">Gholizadeh and Davidson, 2008</xref>]. In 2007, CVD caused about one death per minute among women in the United States, more women’s lives than were claimed by cancer, chronic lower respiratory disease, Alzheimer’s disease, and accidents combined [<xref ref-type="bibr" rid="bibr87-2040622312438935">Roger <italic>et al.</italic> 2011</xref>]. Acknowledging those facts might reduce hypertension-related morbidity and mortality in women.</p>
</sec>
<sec id="section2-2040622312438935">
<title>Epidemiology</title>
<p>The prevalence of hypertension has increased over the last decade [<xref ref-type="bibr" rid="bibr22-2040622312438935">Fields <italic>et al.</italic> 2004</xref>]. Essential hypertension accounts for more than 90% of cases of hypertension [<xref ref-type="bibr" rid="bibr56-2040622312438935">Mancia <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr76-2040622312438935">Oparil <italic>et al.</italic> 2003</xref>] and in a recent review, the lifetime risk of becoming hypertensive in industrialised countries was estimated to exceed 90% [<xref ref-type="bibr" rid="bibr59-2040622312438935">Messerli <italic>et al.</italic> 2007</xref>]. The gender difference in blood pressure levels appears during adolescence [<xref ref-type="bibr" rid="bibr33-2040622312438935">Himmelmann <italic>et al.</italic> 1994</xref>] but a shift in relative prevalence of hypertension occurs in the elderly [<xref ref-type="bibr" rid="bibr44-2040622312438935">Kotchen <italic>et al.</italic> 1982</xref>]. Premenopausal women have lower risk and incidence of hypertension compared with age-matched men but this advantage for women gradually disappears after menopause. After 65 years of age, a higher percentage of women than men have hypertension, and the gap will likely increase with the continued aging of the female population [<xref ref-type="bibr" rid="bibr87-2040622312438935">Roger <italic>et al</italic>. 2011</xref>]. In women between the ages of 65 and 74 years, the prevalence of hypertension is as high as 58%. The prevalence of hypertension among black women is particularly high and CVD rates in the United States are significantly higher for black females compared with their white counterparts [<xref ref-type="bibr" rid="bibr32-2040622312438935">Hertz <italic>et al.</italic> 2005</xref>]. Approximately 40% of stroke cases, 39% of myocardial infarction cases and 28% of end-stage renal diseases are attributable to hypertension [<xref ref-type="bibr" rid="bibr37-2040622312438935">Jones and Nagpal, 2001</xref>; <xref ref-type="bibr" rid="bibr80-2040622312438935">Os <italic>et al.</italic> 1993</xref>]. Furthermore, hypertension, due to its greater prevalence, contributes more to the population burden of heart failure than does myocardial infarction [<xref ref-type="bibr" rid="bibr6-2040622312438935">Bui <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr54-2040622312438935">Lloyd-Jones <italic>et al.</italic> 2002</xref>] and The Rotterdam study indicated that hypertension was more of a contributing factor in women than in men [<xref ref-type="bibr" rid="bibr65-2040622312438935">Mosterd <italic>et al.</italic> 1999</xref>]. The 5-year mortality after the onset of hypertensive heart failure in women is high, about 69% [<xref ref-type="bibr" rid="bibr50-2040622312438935">Levy <italic>et al.</italic> 1996</xref>]. Treatment of hypertension, however, can reduce the incidence of heart failure by almost 50% [<xref ref-type="bibr" rid="bibr11-2040622312438935">Chapman and Neal 2001</xref>; <xref ref-type="bibr" rid="bibr82-2040622312438935">Psaty <italic>et al.</italic> 1997</xref>]. In The Women’s Health Initiative, the major determinants of hypertension prevalence were found to be black race, lower socioeconomic status, history of CVD, and concomitant CVD risk factors of physical inactivity, overweight/obesity, and excess alcohol consumption [<xref ref-type="bibr" rid="bibr100-2040622312438935">Wassertheil-Smoller <italic>et al.</italic> 2000</xref>]. Furthermore, it is of great concern that there is a reverse trend in death rate of coronary heart disease (CHD) in US women aged 35–54 years, most likely due to the obesity epidemic [<xref ref-type="bibr" rid="bibr24-2040622312438935">Ford <italic>et al.</italic> 2007</xref>].</p>
</sec>
<sec id="section3-2040622312438935">
<title>Pathophysiological mechanisms</title>
<p>The reason for gender difference in blood pressure levels is multifactorial and incompletely understood. There are several hypotheses including the potential role of sex hormones, the renin–angiotensin system (RAS), oxidative stress, endothelin, weight gain and sympathetic activation [<xref ref-type="bibr" rid="bibr71-2040622312438935">Nuzzo <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr85-2040622312438935">Reckelhoff, 2001</xref>].</p>
<p>Premenopausal hypertensive women with regular menstrual cycles appear to have lower plasma estradiol levels than age-matched normotensive women [<xref ref-type="bibr" rid="bibr70-2040622312438935">Nordby <italic>et al.</italic> 1992</xref>], and the protective function of oestrogen has been suggested to account for the 10- to 15-year delay in presentation of CVD in women compared with men [<xref ref-type="bibr" rid="bibr75-2040622312438935">Oparil, 2009</xref>]. Natural oestrogens and natural progesterone protect the vasculature from oxidative and inflammatory injury, preventing CVD as reviewed by Dubey and colleagues [<xref ref-type="bibr" rid="bibr16-2040622312438935">Dubey <italic>et al.</italic> 2002</xref>]. Oestrogen increases angiotensinogen levels, and decreases renin levels, angiotensin-converting enzyme (ACE) activity, angiotensin AT-1 receptor density and aldosterone production. Oestrogen also activates counterparts of the RAS as well as improving endothelial function [<xref ref-type="bibr" rid="bibr23-2040622312438935">Fischer <italic>et al.</italic> 2002</xref>]. New intracellular signalling pathways and actions for the cardiovascular protective properties of oestrogen have been proposed [<xref ref-type="bibr" rid="bibr105-2040622312438935">Yang and Reckelhoff, 2011</xref>]. Randomized controlled trials have failed to confirm that hormone replacement therapy affords cardioprotection and have even shown evidence of harm [<xref ref-type="bibr" rid="bibr90-2040622312438935">Rossouw <italic>et al.</italic> 2002</xref>]. However, recent Women’s Health Initiative studies restricted to younger postmenopausal women showed that initiation of hormone replacement therapy closer to menopause reduced the risk of CVD [<xref ref-type="bibr" rid="bibr74-2040622312438935">Oparil, 2006</xref>; <xref ref-type="bibr" rid="bibr100-2040622312438935">Wassertheil-Smoller <italic>et al</italic>. 2000</xref>). More studies are needed if we are to understand the divergent published findings regarding hormone replacement therapy for women.</p>
<p>There is epidemiological [<xref ref-type="bibr" rid="bibr8-2040622312438935">Burt <italic>et al.</italic> 1995</xref>; <xref ref-type="bibr" rid="bibr44-2040622312438935">Kotchen <italic>et al</italic>. 1982</xref>] and experimental evidence [<xref ref-type="bibr" rid="bibr16-2040622312438935">Dubey <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr85-2040622312438935">Reckelhoff, 2001</xref>] that androgens can impact blood pressure regulation in multiple ways [<xref ref-type="bibr" rid="bibr16-2040622312438935">Dubey <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr85-2040622312438935">Reckelhoff, 2001</xref>], through activation of the RAS, blunting of the pressure–natriuresis relationship, and increased endothelin and oxidative stress [<xref ref-type="bibr" rid="bibr85-2040622312438935">Reckelhoff, 2001</xref>], and through the increase of visceral fat [<xref ref-type="bibr" rid="bibr35-2040622312438935">Janssen <italic>et al.</italic> 2010</xref>].</p>
<p>Gender differences in the activity of the RAS could, at least in part, explain the differences in blood pressure levels between men and women [<xref ref-type="bibr" rid="bibr92-2040622312438935">Schunkert <italic>et al.</italic> 1997</xref>]. Lower plasma renin levels have been reported in women with essential hypertension compared with normotensive women [<xref ref-type="bibr" rid="bibr70-2040622312438935">Nordby <italic>et al</italic>. 1992</xref>] and to men [<xref ref-type="bibr" rid="bibr51-2040622312438935">Lewis, 1996</xref>; <xref ref-type="bibr" rid="bibr80-2040622312438935">Os <italic>et al</italic>. 1993</xref>]. Furthermore, plasma renin activity increases after menopause [<xref ref-type="bibr" rid="bibr17-2040622312438935">Duerrschmidt <italic>et al.</italic> 2000</xref>], and the upregulation of angiotensin II receptors and downregulation of angiotensin I receptors after menopause might influence response to therapy.</p>
<p>An interaction between gender and vascular responsiveness has been shown during angiotensin II infusion [<xref ref-type="bibr" rid="bibr60-2040622312438935">Miller <italic>et al.</italic> 1999</xref>]. The Copenhagen City Heart Study showed association between different polymorphism of the angiotensinogen gene and elevated blood pressure in women only [<xref ref-type="bibr" rid="bibr93-2040622312438935">Sethi <italic>et al.</italic> 2003</xref>]. It has also been suggested that ACE, or a nearby gene, could be a sex-specific candidate gene for hypertension [<xref ref-type="bibr" rid="bibr72-2040622312438935">O’Donnell <italic>et al.</italic> 1998</xref>].</p>
<p>Endothelin levels and oxidative stress increase after menopause [<xref ref-type="bibr" rid="bibr71-2040622312438935">Nuzzo <italic>et al</italic>. 2010</xref>], and may affect blood pressure through increased sodium reabsorption and vasoconstriction [<xref ref-type="bibr" rid="bibr25-2040622312438935">Fortepiani <italic>et al.</italic> 2003</xref>; <xref ref-type="bibr" rid="bibr62-2040622312438935">Mortensen <italic>et al.</italic> 1990</xref>].</p>
<p>Obesity and being overweight are increasing more in postmenopausal women than in men [<xref ref-type="bibr" rid="bibr84-2040622312438935">Rappelli, 2002</xref>], and are associated with risk of hypertension and mortality more than in men of the same age [<xref ref-type="bibr" rid="bibr103-2040622312438935">Wilson <italic>et al.</italic> 2002</xref>]. How obesity favours development of hypertension is still a matter of debate, but overactivity of the sympathetic nervous system, insulin resistance, leptin resistance, overactivity of the renin–angiotensin–aldosterone system and a blunted activity of the natriuretic peptides have been implicated [<xref ref-type="bibr" rid="bibr36-2040622312438935">Jarvie and Foody, 2010</xref>]. Increased physical activity and avoidance of excess weight may have large effects on women’s health both on an individual and population level.</p>
<p>Gender appears to be a determinant of autonomic function measured as baroreceptor reflex sensitivity (BRS) and heart rate variability (HRV) in both hypertensive and normotensive subjects [<xref ref-type="bibr" rid="bibr94-2040622312438935">Sevre <italic>et al.</italic> 2001</xref>]. Both hypertensive and normotensive women seem to have attenuated cardiovascular response to stress compared with men [<xref ref-type="bibr" rid="bibr66-2040622312438935">Mundal <italic>et al.</italic> 1993</xref>; <xref ref-type="bibr" rid="bibr89-2040622312438935">Ross <italic>et al.</italic> 2001</xref>]. Sevre and colleagues showed that BRS reduction was more pronounced in women than in men and that systolic blood pressure correlated significantly with BRS in the female hypertensive group only, suggesting that autonomic dysfunction may play a more important role in hypertension in women [<xref ref-type="bibr" rid="bibr94-2040622312438935">Sevre <italic>et al</italic>. 2001</xref>]. The authors speculate on the putative effect of female sex hormones on arterial compliance and modelling, and thus on arterial blood pressure buffer capacity [<xref ref-type="bibr" rid="bibr94-2040622312438935">Sevre <italic>et al</italic>. 2001</xref>]. HRV seems reduced in men and women with hypertension [<xref ref-type="bibr" rid="bibr95-2040622312438935">Singh <italic>et al.</italic> 1998</xref>], and Sevre and colleagues observed that overall HRV was reduced in hypertensive subjects, particularly in women, perhaps through a more pronounced withdrawal of autonomic heart rate control in females.</p>
</sec>
<sec id="section4-2040622312438935">
<title>Cardiovascular risk</title>
<p>Hypertension is an important risk factor for CVD in women. There are specific risk factors in women which may contribute to CVD risk. Preeclampsia has been shown to increase the risk for future hypertension by fourfold, and doubling the risk of future CHD compared with women with uncomplicated pregnancy [<xref ref-type="bibr" rid="bibr38-2040622312438935">Jonsdottir <italic>et al.</italic> 1995</xref>; <xref ref-type="bibr" rid="bibr69-2040622312438935">Nilsson <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr97-2040622312438935">Tan <italic>et al.</italic> 2010</xref>]. It has also been shown that preeclampsia is a risk factor for subsequent end-stage renal disease, although the absolute risk is low [<xref ref-type="bibr" rid="bibr98-2040622312438935">Vikse <italic>et al.</italic> 2008</xref>]. Another important aspect of hypertension in pregnancy is the increased risk of having a low-birthweight infant. As low birthweight is a risk factor for future CHD [<xref ref-type="bibr" rid="bibr3-2040622312438935">Barker <italic>et al.</italic> 1989</xref>; <xref ref-type="bibr" rid="bibr19-2040622312438935">Eriksson <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr18-2040622312438935">Eriksson, 2005</xref>; <xref ref-type="bibr" rid="bibr27-2040622312438935">Frankel <italic>et al.</italic> 1996</xref>; <xref ref-type="bibr" rid="bibr48-2040622312438935">Leon <italic>et al.</italic> 1998</xref>; <xref ref-type="bibr" rid="bibr86-2040622312438935">Rich-Edwards <italic>et al.</italic> 1997</xref>], hypertension in pregnancy can influence the health of the next generation.</p>
<p>Furthermore, autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis have been associated with increased risk of CVD. Whole blood viscosity is closely related to blood pressure and left ventricular hypertrophy (LVH) [<xref ref-type="bibr" rid="bibr15-2040622312438935">de Simone <italic>et al.</italic> 1991</xref>; <xref ref-type="bibr" rid="bibr49-2040622312438935">Letcher <italic>et al.</italic> 1981</xref>], and considered a determinant of cardiovascular risk [<xref ref-type="bibr" rid="bibr13-2040622312438935">de Simone <italic>et al.</italic> 1990</xref>]. Whole blood viscosity is lower in women, both before and after menopause, than in men [<xref ref-type="bibr" rid="bibr26-2040622312438935">Fossum <italic>et al.</italic> 1997</xref>; <xref ref-type="bibr" rid="bibr34-2040622312438935">Hoieggen <italic>et al.</italic> 2000</xref>]. Activation of the sympathetic nervous system during stress may increase whole blood viscosity differently in men and women [<xref ref-type="bibr" rid="bibr89-2040622312438935">Ross <italic>et al</italic>. 2001</xref>]. During stress, platelet function is affected in hypertensive men [<xref ref-type="bibr" rid="bibr46-2040622312438935">Lande <italic>et al.</italic> 1987</xref>, <xref ref-type="bibr" rid="bibr45-2040622312438935">1988</xref>], but not in hypertensive women [<xref ref-type="bibr" rid="bibr66-2040622312438935">Mundal <italic>et al</italic>. 1993</xref>].</p>
<p>Several studies have reported that left ventricular (LV) systolic and diastolic function are gender dependent [<xref ref-type="bibr" rid="bibr2-2040622312438935">Aurigemma and Gaasch 1995</xref>; <xref ref-type="bibr" rid="bibr4-2040622312438935">Bech-Hanssen <italic>et al.</italic> 1999</xref>; <xref ref-type="bibr" rid="bibr5-2040622312438935">Bella <italic>et al.</italic> 2002</xref>; <xref ref-type="bibr" rid="bibr28-2040622312438935">Gerdts <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr47-2040622312438935">Legget <italic>et al.</italic> 1996</xref>]. How gender may influence cardiac adaptation to chronic pressure overload is not fully understood, however, increased hypertrophic response to chronic pressure overload is associated with higher LV ejection fraction in women than in men [<xref ref-type="bibr" rid="bibr9-2040622312438935">Carroll <italic>et al.</italic> 1992</xref>; <xref ref-type="bibr" rid="bibr28-2040622312438935">Gerdts <italic>et al</italic>. 2001</xref>]. Experimental data indicate that myocardial hypertrophy is related to oestrogen in rats, while levels of testosterone do not seem to alter the hypertrophic response [<xref ref-type="bibr" rid="bibr99-2040622312438935">Wallen <italic>et al.</italic> 2000</xref>]. In a study by Gerdts and colleagues, female gender was associated with better LV function [<xref ref-type="bibr" rid="bibr28-2040622312438935">Gerdts <italic>et al</italic>. 2001</xref>]. Obesity, particularly in women, may potentiate the effect of hypertension on LVH [<xref ref-type="bibr" rid="bibr14-2040622312438935">de Simone <italic>et al.</italic> 1994</xref>; <xref ref-type="bibr" rid="bibr28-2040622312438935">Gerdts <italic>et al</italic>. 2001</xref>]. Another explanation could be the difference in LV growth from the first years of life to adulthood. Thus, a relative cardiac hypertrophy in men could contribute to a reduced hypertrophic reserve, and thereby lead to reduced ability to normalize wall stress and less capacity to maintain normal systolic function [<xref ref-type="bibr" rid="bibr43-2040622312438935">Koren <italic>et al.</italic> 1991</xref>].</p>
<p>Microalbuminuria is a marker of cardiovascular and renal risk, and is a sign of target organ damage in essential hypertension [<xref ref-type="bibr" rid="bibr20-2040622312438935">European Society of Hypertension and European Society of Cardiology, 2003</xref>]. Albumin excretion is related to blood pressure levels [<xref ref-type="bibr" rid="bibr61-2040622312438935">Mimran <italic>et al.</italic> 1994</xref>], even in the normoalbuminuric range [<xref ref-type="bibr" rid="bibr7-2040622312438935">Bulatov <italic>et al.</italic> 2001</xref>]. In a recent large-scale population-based study of hypertensive subjects, the association between microalbuminuria and all-cause mortality was found to be stronger in treated males compared with females [<xref ref-type="bibr" rid="bibr88-2040622312438935">Romundstad <italic>et al.</italic> 2003</xref>]. This was the first study to demonstrate a stronger association between microalbuminuria, a marker of endothelial function, and total mortality in hypertensive men than in hypertensive women, and the findings might indicate that hypertensive women tolerate microalbuminuria better than men.</p>
</sec>
<sec id="section5-2040622312438935">
<title>Treatment of hypertension</title>
<p>The attainment of clinical blood pressure goals can markedly reduce cardiovascular morbidity and mortality, yet approximately two-thirds of treated hypertensive women have uncontrolled blood pressure. Data from the National Health and Nutrition Examination Survey (NHANES) showed that hypertensive women were more likely to be treated than men, but less likely to have achieved blood pressure control [<xref ref-type="bibr" rid="bibr31-2040622312438935">Gu <italic>et al.</italic> 2008</xref>]. An interesting observational study from Sweden concluded that female physicians appeared more often to reach the treatment goal for blood pressure in female patients than did male physicians [<xref ref-type="bibr" rid="bibr39-2040622312438935">Journath <italic>et al.</italic> 2008</xref>]. Furthermore, several studies have shown that the blood pressure control rates in women decline dramatically with age [<xref ref-type="bibr" rid="bibr73-2040622312438935">Olsen <italic>et al.</italic> 1999</xref>; <xref ref-type="bibr" rid="bibr100-2040622312438935">Wassertheil-Smoller <italic>et al</italic>. 2000</xref>]. Whether this decline in blood pressure control rates in women is related to biological determinants or to less aggressive treatment is not clear [<xref ref-type="bibr" rid="bibr74-2040622312438935">Oparil, 2006</xref>]. In The Women’s Health Initiative cohort, predictors of lack of blood pressure control were older age, nonwhite race, and the present of insulin-dependent diabetes [<xref ref-type="bibr" rid="bibr100-2040622312438935">Wassertheil-Smoller <italic>et al</italic>. 2000</xref>].</p>
<p>Guidelines for treatment of hypertension are similar for men and women and most do not include a risk stratification for gender. Studies have indicated that with lifestyle modification alone, blood pressure control was worse in women than in men [<xref ref-type="bibr" rid="bibr1-2040622312438935">August and Oparil, 1999</xref>; <xref ref-type="bibr" rid="bibr52-2040622312438935">Lewis <italic>et al.</italic> 1996</xref>], perhaps because weight reduction is harder to obtain in females. Obesity is an important cause of elevated blood pressure in women [<xref ref-type="bibr" rid="bibr102-2040622312438935">Wilsgaard <italic>et al.</italic> 2000</xref>] and with the trend in ongoing increase in average body weight [<xref ref-type="bibr" rid="bibr87-2040622312438935">Roger <italic>et al</italic>. 2011</xref>], focus on weight reduction is extremely important and should be encouraged. Based on the findings of low plasma renin in hypertensive women, salt restriction would be expected to be important for controlling blood pressure in women [<xref ref-type="bibr" rid="bibr81-2040622312438935">Os <italic>et al.</italic> 2004</xref>]. The Dietary Approaches to Stop Hypertension (DASH) trial [<xref ref-type="bibr" rid="bibr91-2040622312438935">Sacks <italic>et al.</italic> 2001</xref>] showed a pronounced antihypertensive effect in women during dietary sodium restriction. This is in accordance with earlier study showing an enhanced depressor response to sodium restriction in elderly normotensive women [<xref ref-type="bibr" rid="bibr68-2040622312438935">Nestel <italic>et al.</italic> 1993</xref>].</p>
<p>In general, antihypertensive efficacy of pharmacological agents is similar in both genders [<xref ref-type="bibr" rid="bibr81-2040622312438935">Os et al. 2004</xref>] and the recommendations to prevent CVD are similar for women and men, with few exceptions [<xref ref-type="bibr" rid="bibr64-2040622312438935">Mosca <italic>et al</italic>. 2011</xref>]. Nevertheless, gender differences in prescription pattern occur in Norway and in other countries with the greater use of diuretics in women [<xref ref-type="bibr" rid="bibr42-2040622312438935">Klungel <italic>et al.</italic> 2000</xref>; <xref ref-type="bibr" rid="bibr73-2040622312438935">Olsen <italic>et al</italic>. 1999</xref>]. One could argue that low plasma renin activity [<xref ref-type="bibr" rid="bibr70-2040622312438935">Nordby <italic>et al</italic>. 1992</xref>] in hypertensive patients favours the use of diuretics, but ACE inhibitors have been shown to have similar antihypertensive efficacy in men and women [<xref ref-type="bibr" rid="bibr77-2040622312438935">Os <italic>et al.</italic> 1991</xref>]. Furthermore, the LIFE study, provided evidence that treatment based on the angiotensin receptor blocker (ARB), losartan, with the addition of thiazide diuretic was superior to the β-blocker, atenolol, plus thiazide diuretic in preventing CVD outcomes in women with LVH, and that the favourable adverse effect profile of losartan-based treatment in hypertensive women at high cardiovascular risk, made it a particularly attractive choice. The treatment effect was consistent in men and women for all of the endpoints tested, with the exception of hospitalization for angina [<xref ref-type="bibr" rid="bibr79-2040622312438935">Os <italic>et al.</italic> 2008</xref>]. On the other hand, in an Australian study, the superior effect of ACE inhibitors compared with hydrochlorthiazide in preventing myocardial infarction was observed only in hypertensive men [<xref ref-type="bibr" rid="bibr104-2040622312438935">Wing <italic>et al.</italic> 2003</xref>]. Other large-scale clinical trials on the effect of antihypertensive treatment on cardiovascular complications have not exposed any gender differences [<xref ref-type="bibr" rid="bibr41-2040622312438935">Kjeldsen <italic>et al.</italic> 2000</xref>, <xref ref-type="bibr" rid="bibr40-2040622312438935">2002</xref>]. In contrast, only hypertensive men had a reduction in cardiovascular events in response to acetylsalicylic acid (ASA) treatment in the Hypertension Optimal Treatment (HOT) study [<xref ref-type="bibr" rid="bibr41-2040622312438935">Kjeldsen <italic>et al</italic>. 2000</xref>]. Although antihypertensive efficacy of pharmacological agents is similar in both genders and guidelines may be applied across all groups, recognizing specific aspects of race and ethnicity when approaching women with hypertension may be beneficial. Black women have higher prevalence of hypertension, they develop hypertension at an earlier age, and their average blood pressure tends to be higher [<xref ref-type="bibr" rid="bibr53-2040622312438935">Lloyd-Jones <italic>et al.</italic> 2010</xref>], contributing to an increased cardiovascular and renal risk in this population [<xref ref-type="bibr" rid="bibr53-2040622312438935">Lloyd-Jones <italic>et al</italic>. 2010</xref>]. African Americans tend to have low plasma renin activity [<xref ref-type="bibr" rid="bibr83-2040622312438935">Rahman <italic>et al.</italic> 1997</xref>] and it has been reported that they respond better to calcium channel blockers and diuretics than to β-blockers or RAS inhibitors. It has been suggested that combination therapy with RAS agents along with calcium channel blockers (CCBs) or diuretics may reduce the differential effect of race/ethnicity on antihypertensive efficacy [<xref ref-type="bibr" rid="bibr21-2040622312438935">Ferdinand and Ferdinand, 2008</xref>]. However, an important fact to bear in mind is that the blockers of RAS are contraindicated in pregnancy due to their teratogenic effect and ought to be used with caution in women who may become pregnant.</p>
<p>Hormone replacement therapy related changes in blood pressure are likely to be modest and should not preclude hormone use in normotensive or hypertensive women when indicated. However, hormone replacement therapy does not appear to reduce blood pressure significantly and should not be prescribed for that indication, nor should it be prescribed for the primary or secondary prevention of CVD [<xref ref-type="bibr" rid="bibr63-2040622312438935">Mosca <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr74-2040622312438935">Oparil, 2006</xref>] .</p>
<p>Hypertension is one of the most important cardiovascular risk factors in women with diabetes [<xref ref-type="bibr" rid="bibr10-2040622312438935">Cederholm <italic>et al.</italic> 2010</xref>]. The importance of strict blood pressure control has proved effective in reducing the risk of stroke and diabetes-related mortality and guidelines have so far advocated a treatment target blood pressure of &lt; 130/80 mmHg [<xref ref-type="bibr" rid="bibr58-2040622312438935">Mansia <italic>et al.</italic> 2007</xref>]. There is, however, an ongoing debate on the advocated blood pressure goal, based on evidence from both randomized controlled trials and observational studies, showing that the benefit for stroke reduction remains at lower blood pressure levels, but the risk of coronary events may be uninfluenced or even increased at lower systolic blood pressure levels [<xref ref-type="bibr" rid="bibr10-2040622312438935">Cederholm <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr12-2040622312438935">Cushman <italic>et al.</italic> 2010</xref>]. This is reflected in a less strict wording in the reappraisal of the European Society of Hypertension guidelines recommending a systolic blood pressure goal of ‘well below’ 140 mmHg in diabetic patients [<xref ref-type="bibr" rid="bibr57-2040622312438935">Mancia <italic>et al.</italic> 2009</xref>].</p>
<p>It has been suggested that some antihypertensive drugs have gender-specific adverse profiles and it is of interest that in the LIFE study and in the THOMS study, women reported side-effects more often than men [<xref ref-type="bibr" rid="bibr67-2040622312438935">Neaton <italic>et al.</italic> 1993</xref>; <xref ref-type="bibr" rid="bibr79-2040622312438935">Os <italic>et al</italic>. 2008</xref>]. Women develop cough related to ACE-inhibitor therapy three times more often than men [<xref ref-type="bibr" rid="bibr78-2040622312438935">Os <italic>et al.</italic> 1994</xref>]. Although men are more likely to develop gout, women are more likely to develop hyponatremia and hypokalemia associated with diuretic therapy [<xref ref-type="bibr" rid="bibr1-2040622312438935">August and Oparil, 1999</xref>]. Furthermore, there is evidence that sexual dysfunction related to antihypertensive therapy may be a problem in women, as well in men [<xref ref-type="bibr" rid="bibr30-2040622312438935">Grimm <italic>et al.</italic> 1997</xref>; <xref ref-type="bibr" rid="bibr101-2040622312438935">Wassertheil-Smoller <italic>et al.</italic> 1991</xref>].</p>
</sec>
<sec id="section6-2040622312438935" sec-type="conclusions">
<title>Conclusion</title>
<p>Hypertension is an important risk factor for CVD in women. Even though women are more at risk to die from hypertension-related CVD than men, women do not perceive CVD as an important health problem. The perception by both patients and physicians that women are at substantial lower risk than men could explain the poorer outcome in women. Better education and information on the importance of treating hypertension is needed and more studies on the interaction between gender and response to antihypertensive drugs are of interest. Furthermore, acknowledgement of risk factors that are unique for women could help preventing the great number of hypertension-related events in women.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<p>The authors declare no conflict of interest in preparing this manuscript.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>August</surname><given-names>P.</given-names></name>
<name><surname>Oparil</surname><given-names>S.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Hypertension in women</article-title>. <source>J Clin Endocrinol Metab</source> <volume>84</volume>: <fpage>1862</fpage>–<lpage>1866</lpage>.</citation>
</ref>
<ref id="bibr2-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aurigemma</surname><given-names>G.P.</given-names></name>
<name><surname>Gaasch</surname><given-names>W.H.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Gender differences in older patients with pressure-overload hypertrophy of the left ventricle</article-title>. <source>Cardiology</source> <volume>86</volume>: <fpage>310</fpage>–<lpage>317</lpage>.</citation>
</ref>
<ref id="bibr3-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barker</surname><given-names>D.J.</given-names></name>
<name><surname>Winter</surname><given-names>P.D.</given-names></name>
<name><surname>Osmond</surname><given-names>C.</given-names></name>
<name><surname>Margetts</surname><given-names>B.</given-names></name>
<name><surname>Simmonds</surname><given-names>S.J.</given-names></name>
</person-group> (<year>1989</year>) <article-title>Weight in infancy and death from ischaemic heart disease</article-title>. <source>Lancet</source> <volume>2</volume>: <fpage>577</fpage>–<lpage>580</lpage>.</citation>
</ref>
<ref id="bibr4-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bech-Hanssen</surname><given-names>O.</given-names></name>
<name><surname>Wallentin</surname><given-names>I.</given-names></name>
<name><surname>Houltz</surname><given-names>E.</given-names></name>
<name><surname>Beckman</surname><given-names>S.M.</given-names></name>
<name><surname>Larsson</surname><given-names>S.</given-names></name>
<name><surname>Caidahl</surname><given-names>K.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Gender differences in patients with severe aortic stenosis: impact on preoperative left ventricular geometry and function, as well as early postoperative morbidity and mortality</article-title>. <source>Eur J Cardio-Thoracic Surg</source> <volume>15</volume>: <fpage>24</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr5-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bella</surname><given-names>J.N.</given-names></name>
<name><surname>Palmieri</surname><given-names>V.</given-names></name>
<name><surname>Kitzman</surname><given-names>D.W.</given-names></name>
<name><surname>Liu</surname><given-names>J.E.</given-names></name>
<name><surname>Oberman</surname><given-names>A.</given-names></name>
<name><surname>Hunt</surname><given-names>S.C.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Gender difference in diastolic function in hypertension (the HyperGEN study)</article-title>. <source>Am J Cardiol</source> <volume>89</volume>: <fpage>1052</fpage>–<lpage>1056</lpage>.</citation>
</ref>
<ref id="bibr6-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bui</surname><given-names>A.L.</given-names></name>
<name><surname>Horwich</surname><given-names>T.B.</given-names></name>
<name><surname>Fonarow</surname><given-names>G.C.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Epidemiology and risk profile of heart failure</article-title>. <source>Nat Rev Cardiol</source> <volume>8</volume>: <fpage>30</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr7-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bulatov</surname><given-names>V.A.</given-names></name>
<name><surname>Stenehjem</surname><given-names>A.</given-names></name>
<name><surname>Os</surname><given-names>I.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Left ventricular mass assessed by electrocardiography and albumin excretion rate as a continuum in untreated essential hypertension</article-title>. <source>J Hypertension</source> <volume>19</volume>: <fpage>1473</fpage>–<lpage>1478</lpage>.</citation>
</ref>
<ref id="bibr8-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burt</surname><given-names>V.L.</given-names></name>
<name><surname>Whelton</surname><given-names>P.</given-names></name>
<name><surname>Roccella</surname><given-names>E.J.</given-names></name>
<name><surname>Brown</surname><given-names>C.</given-names></name>
<name><surname>Cutler</surname><given-names>J.A.</given-names></name>
<name><surname>Higgins</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>1995</year>) <article-title>Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991</article-title>. <source>Hypertension</source> <volume>25</volume>: <fpage>305</fpage>–<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr9-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carroll</surname><given-names>J.D.</given-names></name>
<name><surname>Carroll</surname><given-names>E.P.</given-names></name>
<name><surname>Feldman</surname><given-names>T.</given-names></name>
<name><surname>Ward</surname><given-names>D.M.</given-names></name>
<name><surname>Lang</surname><given-names>R.M.</given-names></name>
<name><surname>McGaughey</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>1992</year>) <article-title>Sex-associated differences in left ventricular function in aortic stenosis of the elderly</article-title>. <source>Circulation</source> <volume>86</volume>: <fpage>1099</fpage>–<lpage>1107</lpage>.</citation>
</ref>
<ref id="bibr10-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cederholm</surname><given-names>J.</given-names></name>
<name><surname>Gudbjornsdottir</surname><given-names>S.</given-names></name>
<name><surname>Eliasson</surname><given-names>B.</given-names></name>
<name><surname>Zethelius</surname><given-names>B.</given-names></name>
<name><surname>Eeg-Olofsson</surname><given-names>K.</given-names></name>
<name><surname>Nilsson</surname><given-names>P.M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish national diabetes register</article-title>. <source>J Hypertens</source> <volume>28</volume>: <fpage>2026</fpage>–<lpage>2035</lpage>.</citation>
</ref>
<ref id="bibr11-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chapman</surname><given-names>N.</given-names></name>
<name><surname>Neal</surname><given-names>B.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes</article-title>. <source>Curr Hypertens Rep</source> <volume>3</volume>: <fpage>340</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr12-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cushman</surname><given-names>W.C.</given-names></name>
<name><surname>Evans</surname><given-names>G.W.</given-names></name>
<name><surname>Byington</surname><given-names>R.P.</given-names></name>
<name><surname>Goff</surname><given-names>D.C.</given-names><suffix>Jr</suffix></name>
<name><surname>Grimm</surname><given-names>R.H.</given-names><suffix>Jr</suffix></name>
<name><surname>Cutler</surname><given-names>J.A.</given-names></name><etal/>
</person-group>. <year>2010</year>. Effects of intensive blood-pressure control in type 2 diabetes mellitus. <source>N Engl J Med</source> <volume>362</volume>: <fpage>1575</fpage>–<lpage>1585</lpage>.</citation>
</ref>
<ref id="bibr13-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Simone</surname><given-names>G.</given-names></name>
<name><surname>Devereux</surname><given-names>R.B.</given-names></name>
<name><surname>Chien</surname><given-names>S.</given-names></name>
<name><surname>Alderman</surname><given-names>M.H.</given-names></name>
<name><surname>Atlas</surname><given-names>S.A.</given-names></name>
<name><surname>Laragh</surname><given-names>J.H.</given-names></name>
</person-group> (<year>1990</year>) <article-title>Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults</article-title>. <source>Circulation</source> <volume>81</volume>: <fpage>107</fpage>–<lpage>117</lpage>.</citation>
</ref>
<ref id="bibr14-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Simone</surname><given-names>G.</given-names></name>
<name><surname>Devereux</surname><given-names>R.B.</given-names></name>
<name><surname>Roman</surname><given-names>M.J.</given-names></name>
<name><surname>Alderman</surname><given-names>M.H.</given-names></name>
<name><surname>Laragh</surname><given-names>J.H.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults</article-title>. <source>Hypertension</source> <volume>23</volume>: <fpage>600</fpage>–<lpage>606</lpage>.</citation>
</ref>
<ref id="bibr15-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Simone</surname><given-names>G.</given-names></name>
<name><surname>Devereux</surname><given-names>R.B.</given-names></name>
<name><surname>Roman</surname><given-names>M.J.</given-names></name>
<name><surname>Ganau</surname><given-names>A.</given-names></name>
<name><surname>Chien</surname><given-names>S.</given-names></name>
<name><surname>Alderman</surname><given-names>M.H.</given-names></name><etal/>
</person-group>. (<year>1991</year>) <article-title>Gender differences in left ventricular anatomy, blood viscosity and volume regulatory hormones in normal adults</article-title>. <source>Am J Cardiol</source> <volume>68</volume>: <fpage>1704</fpage>–<lpage>1708</lpage>.</citation>
</ref>
<ref id="bibr16-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dubey</surname><given-names>R.K.</given-names></name>
<name><surname>Oparil</surname><given-names>S.</given-names></name>
<name><surname>Imthurn</surname><given-names>B.</given-names></name>
<name><surname>Jackson</surname><given-names>E.K.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Sex hormones and hypertension</article-title>. <source>Cardiovasc Res</source> <volume>53</volume>: <fpage>688</fpage>–<lpage>708</lpage>.</citation>
</ref>
<ref id="bibr17-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Duerrschmidt</surname><given-names>N.</given-names></name>
<name><surname>Wippich</surname><given-names>N.</given-names></name>
<name><surname>Goettsch</surname><given-names>W.</given-names></name>
<name><surname>Broemme</surname><given-names>H.J.</given-names></name>
<name><surname>Morawietz</surname><given-names>H.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Endothelin-1 induces NAD(P)H oxidase in human endothelial cells</article-title>. <source>Biochem Biophys Res Commun</source> <volume>269</volume>: <fpage>713</fpage>–<lpage>717</lpage>.</citation>
</ref>
<ref id="bibr18-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eriksson</surname><given-names>J.G.</given-names></name>
</person-group> (<year>2005</year>) <article-title>The fetal origins hypothesis—10 years on</article-title>. <source>BMJ</source> <volume>330</volume>: <fpage>1096</fpage>–<lpage>1097</lpage>.</citation>
</ref>
<ref id="bibr19-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eriksson</surname><given-names>J.G.</given-names></name>
<name><surname>Forsen</surname><given-names>T.</given-names></name>
<name><surname>Tuomilehto</surname><given-names>J.</given-names></name>
<name><surname>Osmond</surname><given-names>C.</given-names></name>
<name><surname>Barker</surname><given-names>D.J.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Early growth and coronary heart disease in later life: longitudinal study</article-title>. <source>BMJ</source> <volume>322</volume>: <fpage>949</fpage>–<lpage>953</lpage>.</citation>
</ref>
<ref id="bibr20-2040622312438935">
<citation citation-type="journal">
<collab>European Society of Hypertension and European Society of Cardiology</collab> (<year>2003</year>) <article-title>2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension</article-title>. <source>J Hypertens</source> <volume>21</volume>: <fpage>1011</fpage>–<lpage>1053</lpage>.</citation>
</ref>
<ref id="bibr21-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferdinand</surname><given-names>K.C.</given-names></name>
<name><surname>Ferdinand</surname><given-names>D.P.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Race-based therapy for hypertension: possible benefits and potential pitfalls</article-title>. <source>Expert Rev Cardiovasc Ther</source> <volume>6</volume>: <fpage>1357</fpage>–<lpage>1366</lpage>.</citation>
</ref>
<ref id="bibr22-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fields</surname><given-names>L.E.</given-names></name>
<name><surname>Burt</surname><given-names>V.L.</given-names></name>
<name><surname>Cutler</surname><given-names>J.A.</given-names></name>
<name><surname>Hughes</surname><given-names>J.</given-names></name>
<name><surname>Roccella</surname><given-names>E.J.</given-names></name>
<name><surname>Sorlie</surname><given-names>P.</given-names></name>
</person-group> <year>2004</year>. <article-title>The burden of adult hypertension in the United States 1999 to 2000: a rising tide</article-title>. <source>Hypertension</source> <volume>44</volume>: <fpage>398</fpage>–<lpage>404</lpage>.</citation>
</ref>
<ref id="bibr23-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>M.</given-names></name>
<name><surname>Baessler</surname><given-names>A.</given-names></name>
<name><surname>Schunkert</surname><given-names>H.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Renin angiotensin system and gender differences in the cardiovascular system</article-title>. <source>Cardiovasc Res</source> <volume>53</volume>: <fpage>672</fpage>–<lpage>677</lpage>.</citation>
</ref>
<ref id="bibr24-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ford</surname><given-names>E.S.</given-names></name>
<name><surname>Ajani</surname><given-names>U.A.</given-names></name>
<name><surname>Croft</surname><given-names>J.B.</given-names></name>
<name><surname>Critchley</surname><given-names>J.A.</given-names></name>
<name><surname>Labarthe</surname><given-names>D.R.</given-names></name>
<name><surname>Kottke</surname><given-names>T.E.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Explaining the decrease in U.S. deaths from coronary disease, 1980-2000</article-title>. <source>N Engl J Med</source> <volume>356</volume>: <fpage>2388</fpage>–<lpage>2398</lpage>.</citation>
</ref>
<ref id="bibr25-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fortepiani</surname><given-names>L.A.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Racusen</surname><given-names>L.</given-names></name>
<name><surname>Roberts</surname><given-names>L.J.</given-names></name>
<name><surname>Reckelhoff</surname><given-names>J.F.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Characterization of an animal model of postmenopausal hypertension in spontaneously hypertensive rats</article-title>. <source>Hypertension</source> <volume>41</volume>: <fpage>640</fpage>–<lpage>645</lpage>.</citation>
</ref>
<ref id="bibr26-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fossum</surname><given-names>E.</given-names></name>
<name><surname>Hoieggen</surname><given-names>A.</given-names></name>
<name><surname>Moan</surname><given-names>A.</given-names></name>
<name><surname>Nordby</surname><given-names>G.</given-names></name>
<name><surname>Velund</surname><given-names>T.L.</given-names></name>
<name><surname>Kjeldsen</surname><given-names>S.E.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Whole blood viscosity, blood pressure and cardiovascular risk factors in healthy blood donors</article-title>. <source>Blood Press</source> <volume>6</volume>: <fpage>161</fpage>–<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr27-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frankel</surname><given-names>S.</given-names></name>
<name><surname>Elwood</surname><given-names>P.</given-names></name>
<name><surname>Sweetnam</surname><given-names>P.</given-names></name>
<name><surname>Yarnell</surname><given-names>J.</given-names></name>
<name><surname>Smith</surname><given-names>G.D.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Birthweight, body-mass index in middle age, and incident coronary heart disease</article-title>. <source>Lancet</source> <volume>348</volume>: <fpage>1478</fpage>–<lpage>1480</lpage>.</citation>
</ref>
<ref id="bibr28-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerdts</surname><given-names>E.</given-names></name>
<name><surname>Zabalgoitia</surname><given-names>M.</given-names></name>
<name><surname>Bjornstad</surname><given-names>H.</given-names></name>
<name><surname>Svendsen</surname><given-names>T.L.</given-names></name>
<name><surname>Devereux</surname><given-names>R.B.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study)</article-title>. <source>Am J Cardiol</source> <volume>87</volume>: <fpage>980</fpage>–<lpage>983</lpage>.</citation>
</ref>
<ref id="bibr29-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gholizadeh</surname><given-names>L.</given-names></name>
<name><surname>Davidson</surname><given-names>P.</given-names></name>
</person-group> (<year>2008</year>) <article-title>More similarities than differences: an international comparison of CVD mortality and risk factors in women</article-title>. <source>Health Care Women Int</source> <volume>29</volume>: <fpage>3</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr30-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grimm</surname><given-names>R.H.</given-names><suffix>Jr</suffix></name>
<name><surname>Grandits</surname><given-names>G.A.</given-names></name>
<name><surname>Prineas</surname><given-names>R.J.</given-names></name>
<name><surname>McDonald</surname><given-names>R.H.</given-names></name>
<name><surname>Lewis</surname><given-names>C.E.</given-names></name>
<name><surname>Flack</surname><given-names>J.M.</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)</article-title>. <source>Hypertension</source> <volume>29</volume>: <fpage>8</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr31-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gu</surname><given-names>Q.</given-names></name>
<name><surname>Burt</surname><given-names>V.L.</given-names></name>
<name><surname>Paulose-Ram</surname><given-names>R.</given-names></name>
<name><surname>Dillon</surname><given-names>C.F.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999–2004</article-title>. <source>Am J Hypertens</source> <volume>21</volume>: <fpage>789</fpage>–<lpage>798</lpage>.</citation>
</ref>
<ref id="bibr32-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hertz</surname><given-names>R.P.</given-names></name>
<name><surname>Unger</surname><given-names>A.N.</given-names></name>
<name><surname>Cornell</surname><given-names>J.A.</given-names></name>
<name><surname>Saunders</surname><given-names>E.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Racial disparities in hypertension prevalence, awareness, and management</article-title>. <source>Arch Intern Med</source> <volume>165</volume>: <fpage>2098</fpage>–<lpage>2104</lpage>.</citation>
</ref>
<ref id="bibr33-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Himmelmann</surname><given-names>A.</given-names></name>
<name><surname>Svensson</surname><given-names>A.</given-names></name>
<name><surname>Hansson</surname><given-names>L.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Influence of sex on blood pressure and left ventricular mass in adolescents: the Hypertension in Pregnancy Offspring Study</article-title>. <source>J Human Hypertens</source> <volume>8</volume>: <fpage>485</fpage>–<lpage>490</lpage>.</citation>
</ref>
<ref id="bibr34-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoieggen</surname><given-names>A.</given-names></name>
<name><surname>Fossum</surname><given-names>E.</given-names></name>
<name><surname>Nesbitt</surname><given-names>S.D.</given-names></name>
<name><surname>Palmieri</surname><given-names>V.</given-names></name>
<name><surname>Kjeldsen</surname><given-names>S.E.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Blood viscosity, plasma adrenaline and fasting insulin in hypertensive patients with left ventricular hypertrophy. ICARUS, a LIFE Substudy. Insulin CARotids US Scandinavica</article-title>. <source>Blood Press</source> <volume>9</volume>: <fpage>83</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr35-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Janssen</surname><given-names>I.</given-names></name>
<name><surname>Powell</surname><given-names>L.H.</given-names></name>
<name><surname>Kazlauskaite</surname><given-names>R.</given-names></name>
<name><surname>Dugan</surname><given-names>S.A.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Testosterone and visceral fat in midlife women: the Study of Women’s Health Across the Nation (SWAN) fat patterning study</article-title>. <source>Obesity (Silver Spring)</source> <volume>18</volume>: <fpage>604</fpage>–<lpage>610</lpage>.</citation>
</ref>
<ref id="bibr36-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jarvie</surname><given-names>J.L.</given-names></name>
<name><surname>Foody</surname><given-names>J.M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Recognizing and improving health care disparities in the prevention of cardiovascular disease in women</article-title>. <source>Curr Cardiol Rep</source> <volume>12</volume>: <fpage>488</fpage>–<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr37-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>C.A.</given-names></name>
<name><surname>Nagpal</surname><given-names>S.</given-names></name>
</person-group> (<year>2001</year>) <article-title>An update: women, hypertension and therapeutic efficacy</article-title>. <source>Can J Cardiol</source> <volume>17</volume>: <fpage>1283</fpage>–<lpage>1289</lpage>.</citation>
</ref>
<ref id="bibr38-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jonsdottir</surname><given-names>L.S.</given-names></name>
<name><surname>Arngrimsson</surname><given-names>R.</given-names></name>
<name><surname>Geirsson</surname><given-names>R.T.</given-names></name>
<name><surname>Sigvaldason</surname><given-names>H.</given-names></name>
<name><surname>Sigfusson</surname><given-names>N.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Death rates from ischemic heart disease in women with a history of hypertension in pregnancy</article-title>. <source>Acta Obstet Gynecol Scand</source> <volume>74</volume>: <fpage>772</fpage>–<lpage>776</lpage>.</citation>
</ref>
<ref id="bibr39-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Journath</surname><given-names>G.</given-names></name>
<name><surname>Hellenius</surname><given-names>M.L.</given-names></name>
<name><surname>Manhem</surname><given-names>K.</given-names></name>
<name><surname>Kjellgren</surname><given-names>K.I.</given-names></name>
<name><surname>Nilsson</surname><given-names>P.M.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Association of physician’s sex with risk factor control in treated hypertensive patients from Swedish primary healthcare</article-title>. <source>J Hypertens</source> <volume>26</volume>: <fpage>2050</fpage>–<lpage>2056</lpage>.</citation>
</ref>
<ref id="bibr40-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kjeldsen</surname><given-names>S.E.</given-names></name>
<name><surname>Hedner</surname><given-names>T.</given-names></name>
<name><surname>Syvertsen</surname><given-names>J.O.</given-names></name>
<name><surname>Lund-Johansen</surname><given-names>P.</given-names></name>
<name><surname>Hansson</surname><given-names>L.</given-names></name>
<name><surname>Lanke</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study</article-title>. <source>J Hypertens</source> <volume>20</volume>: <fpage>1231</fpage>–<lpage>1237</lpage>.</citation>
</ref>
<ref id="bibr41-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kjeldsen</surname><given-names>S.E.</given-names></name>
<name><surname>Warnold</surname><given-names>I.</given-names></name>
<name><surname>Hansson</surname><given-names>L.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Influence of gender on prevention of myocardial infarction by antihypertensives and acetylsalicylic acid: the HOT study</article-title>. <source>J Gend Specif Med</source> <volume>3</volume>(<issue>8</issue>): <fpage>35</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr42-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klungel</surname><given-names>O.H.</given-names></name>
<name><surname>Paes</surname><given-names>A.H.</given-names></name>
<name><surname>de</surname><given-names>Boer. A.</given-names></name>
<name><surname>Kuyvenhoven</surname><given-names>M.M.</given-names></name>
<name><surname>Seidell</surname><given-names>J.C.</given-names></name>
<name><surname>Bakker</surname><given-names>A.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Sex differences in the medication choice for hypertension in general practice. A study with written case simulations</article-title>. <source>Pharm World Sci</source> <volume>22</volume>: <fpage>140</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr43-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koren</surname><given-names>M.J.</given-names></name>
<name><surname>Devereux</surname><given-names>R.B.</given-names></name>
<name><surname>Casale</surname><given-names>P.N.</given-names></name>
<name><surname>Savage</surname><given-names>D.D.</given-names></name>
<name><surname>Laragh</surname><given-names>J.H.</given-names></name>
</person-group> (<year>1991</year>) <article-title>Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension</article-title>. <source>Ann Intern Med</source> <volume>114</volume>: <fpage>345</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr44-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kotchen</surname><given-names>J.M.</given-names></name>
<name><surname>McKean</surname><given-names>H.E.</given-names></name>
<name><surname>Kotchen</surname><given-names>T.A.</given-names></name>
</person-group> (<year>1982</year>) <article-title>Blood pressure trends with aging</article-title>. <source>Hypertension</source> <volume>4</volume>(<issue>5 Pt 2</issue>): <fpage>III128</fpage>–<lpage>III134</lpage>.</citation>
</ref>
<ref id="bibr45-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lande</surname><given-names>K.</given-names></name>
<name><surname>Kjeldsen</surname><given-names>S.E.</given-names></name>
<name><surname>Os</surname><given-names>I.</given-names></name>
<name><surname>Westheim</surname><given-names>A.</given-names></name>
<name><surname>Hjermann</surname><given-names>I.</given-names></name>
<name><surname>Eide</surname><given-names>I.</given-names></name><etal/>
</person-group>. (<year>1988</year>) <article-title>Increased platelet and vascular smooth muscle reactivity to low-dose adrenaline infusion in mild essential hypertension</article-title>. <source>J Hypertens</source> <volume>6</volume>: <fpage>219</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr46-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lande</surname><given-names>K.</given-names></name>
<name><surname>Os</surname><given-names>I.</given-names></name>
<name><surname>Kjeldsen</surname><given-names>S.E.</given-names></name>
<name><surname>Westheim</surname><given-names>A.</given-names></name>
<name><surname>Hjermann</surname><given-names>I.</given-names></name>
<name><surname>Eide</surname><given-names>I.</given-names></name><etal/>
</person-group>. (<year>1987</year>) <article-title>Increased platelet size and release reaction in essential hypertension</article-title>. <source>J Hypertens</source> <volume>5</volume>: <fpage>401</fpage>–<lpage>406</lpage>.</citation>
</ref>
<ref id="bibr47-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Legget</surname><given-names>M.E.</given-names></name>
<name><surname>Kuusisto</surname><given-names>J.</given-names></name>
<name><surname>Healy</surname><given-names>N.L.</given-names></name>
<name><surname>Fujioka</surname><given-names>M.</given-names></name>
<name><surname>Schwaegler</surname><given-names>R.G.</given-names></name>
<name><surname>Otto</surname><given-names>C.M.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Gender differences in left ventricular function at rest and with exercise in asymptomatic aortic stenosis</article-title>. <source>Am Heart J</source> <volume>131</volume>: <fpage>94</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr48-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leon</surname><given-names>D.A.</given-names></name>
<name><surname>Lithell</surname><given-names>H.O.</given-names></name>
<name><surname>Vagero</surname><given-names>D.</given-names></name>
<name><surname>Koupilova</surname><given-names>I.</given-names></name>
<name><surname>Mohsen</surname><given-names>R.</given-names></name>
<name><surname>Berglund</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Reduced fetal growth rate and increased risk of death from ischaemic heart disease: cohort study of 15 000 Swedish men and women born 1915–29</article-title>. <source>BMJ</source> <volume>317</volume>: <fpage>241</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr49-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Letcher</surname><given-names>R.L.</given-names></name>
<name><surname>Chien</surname><given-names>S.</given-names></name>
<name><surname>Pickering</surname><given-names>T.G.</given-names></name>
<name><surname>Sealey</surname><given-names>J.E.</given-names></name>
<name><surname>Laragh</surname><given-names>J.H.</given-names></name>
</person-group> (<year>1981</year>) <article-title>Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Role of fibrinogen and concentration</article-title>. <source>Am J Med</source> <volume>70</volume>: <fpage>1195</fpage>–<lpage>1202</lpage>.</citation>
</ref>
<ref id="bibr50-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levy</surname><given-names>D.</given-names></name>
<name><surname>Larson</surname><given-names>M.G.</given-names></name>
<name><surname>Vasan</surname><given-names>R.S.</given-names></name>
<name><surname>Kannel</surname><given-names>W.B.</given-names></name>
<name><surname>Ho</surname><given-names>K.K.</given-names></name>
</person-group> (<year>1996</year>) <article-title>The progression from hypertension to congestive heart failure</article-title>. <source>JAMA</source> <volume>275</volume>: <fpage>1557</fpage>–<lpage>1562</lpage>.</citation>
</ref>
<ref id="bibr51-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>C.E.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Characteristics and treatment of hypertension in women: a review of the literature</article-title>. <source>Am J Med Sci</source> <volume>311</volume>: <fpage>193</fpage>–<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr52-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>C.E.</given-names></name>
<name><surname>Grandits</surname><given-names>A.</given-names></name>
<name><surname>Flack</surname><given-names>J.</given-names></name>
<name><surname>McDonald</surname><given-names>R.</given-names></name>
<name><surname>Elmer</surname><given-names>P.J.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study</article-title>. <source>Arch Intern Med</source> <volume>156</volume>: <fpage>377</fpage>–<lpage>385</lpage>.</citation>
</ref>
<ref id="bibr53-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lloyd-Jones</surname><given-names>D.</given-names></name>
<name><surname>Adams</surname><given-names>R.J.</given-names></name>
<name><surname>Brown</surname><given-names>T.M.</given-names></name>
<name><surname>Carnethon</surname><given-names>M.</given-names></name>
<name><surname>Dai</surname><given-names>S.</given-names></name>
<name><surname>de</surname><given-names>Simone G.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Heart disease and stroke statistics—2010 update: a report from the American Heart Association</article-title>. <source>Circulation</source> <volume>121</volume>(<issue>7</issue>): <fpage>e46</fpage>–<lpage>e215</lpage>.</citation>
</ref>
<ref id="bibr54-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lloyd-Jones</surname><given-names>D.M.</given-names></name>
<name><surname>Larson</surname><given-names>M.G.</given-names></name>
<name><surname>Leip</surname><given-names>E.P.</given-names></name>
<name><surname>Beiser</surname><given-names>A.</given-names></name>
<name><surname>D’Agostino</surname><given-names>R.B.</given-names></name>
<name><surname>Kannel</surname><given-names>W.B.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Lifetime risk for developing congestive heart failure: the Framingham Heart Study</article-title>. <source>Circulation</source> <volume>106</volume>: <fpage>3068</fpage>–<lpage>3072</lpage>.</citation>
</ref>
<ref id="bibr55-2040622312438935">
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Maas</surname><given-names>A.H.</given-names></name>
<name><surname>van der Schouw</surname><given-names>Y.T.</given-names></name>
<name><surname>Regitz-Zagrosek</surname><given-names>V.</given-names></name>
<name><surname>Swahn</surname><given-names>E.</given-names></name>
<name><surname>Appelman</surname><given-names>Y.E.</given-names></name>
<name><surname>Pasterkamp</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Red alert for women’s heart: the urgent need for more research and knowledge on cardiovascular disease in women: proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010</article-title>. <source>Eur Heart J</source> <volume>32</volume>: <fpage>1362</fpage>–<lpage>1368</lpage>.</citation>
</ref>
<ref id="bibr56-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mancia</surname><given-names>G.</given-names></name>
<name><surname>De</surname><given-names>Backer G.</given-names></name>
<name><surname>Dominiczak</surname><given-names>A.</given-names></name>
<name><surname>Cifkova</surname><given-names>R.</given-names></name>
<name><surname>Fagard</surname><given-names>R.</given-names></name>
<name><surname>Germano</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</article-title>. <source>J Hypertens</source> <volume>25</volume>: <fpage>1105</fpage>–<lpage>1187</lpage>.</citation>
</ref>
<ref id="bibr57-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mancia</surname><given-names>G.</given-names></name>
<name><surname>Laurent</surname><given-names>S.</given-names></name>
<name><surname>Agabiti-Rosei</surname><given-names>E.</given-names></name>
<name><surname>Ambrosioni</surname><given-names>E.</given-names></name>
<name><surname>Burnier</surname><given-names>M.</given-names></name>
<name><surname>Caulfield</surname><given-names>M.J.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document</article-title>. <source>Blood Press</source> <volume>18</volume>: <fpage>308</fpage>–<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr58-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mansia</surname><given-names>G.</given-names></name>
<name><surname>De</surname><given-names>Backer G.</given-names></name>
<name><surname>Dominiczak</surname><given-names>A.</given-names></name>
<name><surname>Cifkova</surname><given-names>R.</given-names></name>
<name><surname>Fagard</surname><given-names>R.</given-names></name>
<name><surname>Germano</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</article-title>. <source>Blood Press</source> <volume>16</volume>: <fpage>135</fpage>–<lpage>232</lpage>.</citation>
</ref>
<ref id="bibr59-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Messerli</surname><given-names>F.H.</given-names></name>
<name><surname>Williams</surname><given-names>B.</given-names></name>
<name><surname>Ritz</surname><given-names>E.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Essential hypertension</article-title>. <source>Lancet</source> <volume>370</volume>: <fpage>591</fpage>–<lpage>603</lpage>.</citation>
</ref>
<ref id="bibr60-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>J.A.</given-names></name>
<name><surname>Anacta</surname><given-names>L.A.</given-names></name>
<name><surname>Cattran</surname><given-names>D.C.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Impact of gender on the renal response to angiotensin II</article-title>. <source>Kidney Int</source> <volume>55</volume>: <fpage>278</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr61-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mimran</surname><given-names>A.</given-names></name>
<name><surname>Ribstein</surname><given-names>J.</given-names></name>
<name><surname>DuCailar</surname><given-names>G.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension?</article-title> <source>Hypertension</source> <volume>23</volume>: <fpage>1018</fpage>–<lpage>1021</lpage>.</citation>
</ref>
<ref id="bibr62-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mortensen</surname><given-names>L.H.</given-names></name>
<name><surname>Pawloski</surname><given-names>C.M.</given-names></name>
<name><surname>Kanagy</surname><given-names>N.L.</given-names></name>
<name><surname>Fink</surname><given-names>G.D.</given-names></name>
</person-group> (<year>1990</year>) <article-title>Chronic hypertension produced by infusion of endothelin in rats</article-title>. <source>Hypertension</source> <volume>15</volume>: <fpage>729</fpage>–<lpage>733</lpage>.</citation>
</ref>
<ref id="bibr63-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mosca</surname><given-names>L.</given-names></name>
<name><surname>Appel</surname><given-names>L.J.</given-names></name>
<name><surname>Benjamin</surname><given-names>E.J.</given-names></name>
<name><surname>Berra</surname><given-names>K.</given-names></name>
<name><surname>Chandra-Strobos</surname><given-names>N.</given-names></name>
<name><surname>Fabunmi</surname><given-names>R.P.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Evidence-based guidelines for cardiovascular disease prevention in women</article-title>. <source>Circulation</source> <volume>109</volume>: <fpage>672</fpage>–<lpage>693</lpage>.</citation>
</ref>
<ref id="bibr64-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mosca</surname><given-names>L.</given-names></name>
<name><surname>Benjamin</surname><given-names>E.J.</given-names></name>
<name><surname>Berra</surname><given-names>K.</given-names></name>
<name><surname>Bezanson</surname><given-names>J.L.</given-names></name>
<name><surname>Dolor</surname><given-names>R.J.</given-names></name>
<name><surname>Lloyd-Jones</surname><given-names>D.M.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association</article-title>. <source>Circulation</source> <volume>123</volume>: <fpage>1243</fpage>–<lpage>1262</lpage>.</citation>
</ref>
<ref id="bibr65-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mosterd</surname><given-names>A.</given-names></name>
<name><surname>Hoes</surname><given-names>A.W.</given-names></name>
<name><surname>de Bruyne</surname><given-names>M.C.</given-names></name>
<name><surname>Deckers</surname><given-names>J.W.</given-names></name>
<name><surname>Linker</surname><given-names>D.T.</given-names></name>
<name><surname>Hofman</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study</article-title>. <source>Eur Heart J</source> <volume>20</volume>: <fpage>447</fpage>–<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr66-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mundal</surname><given-names>H.H.</given-names></name>
<name><surname>Nordby</surname><given-names>G.</given-names></name>
<name><surname>Lande</surname><given-names>K.</given-names></name>
<name><surname>Gjesdal</surname><given-names>K.</given-names></name>
<name><surname>Kjeldsen</surname><given-names>S.E.</given-names></name>
<name><surname>Os</surname><given-names>I.</given-names></name>
</person-group> (<year>1993</year>) <article-title>Effect of cold pressor test and awareness of hypertension on platelet function in normotensive and hypertensive women</article-title>. <source>Scand J Clin Lab Invest</source> <volume>53</volume>: <fpage>585</fpage>–<lpage>591</lpage>.</citation>
</ref>
<ref id="bibr67-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neaton</surname><given-names>J.D.</given-names></name>
<name><surname>Grimm</surname><given-names>R.H.</given-names><suffix>Jr</suffix></name>
<name><surname>Prineas</surname><given-names>R.J.</given-names></name>
<name><surname>Stamler</surname><given-names>J.</given-names></name>
<name><surname>Grandits</surname><given-names>G.A.</given-names></name>
<name><surname>Elmer</surname><given-names>P.J.</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Treatment of mild hypertension study. Final results. Treatment of Mild Hypertension Study Research Group</article-title>. <source>JAMA</source> <volume>270</volume>: <fpage>713</fpage>–<lpage>724</lpage>.</citation>
</ref>
<ref id="bibr68-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nestel</surname><given-names>P.J.</given-names></name>
<name><surname>Clifton</surname><given-names>P.M.</given-names></name>
<name><surname>Noakes</surname><given-names>M.</given-names></name>
<name><surname>McArthur</surname><given-names>R.</given-names></name>
<name><surname>Howe</surname><given-names>P.R.</given-names></name>
</person-group> (<year>1993</year>) <article-title>Enhanced blood pressure response to dietary salt in elderly women, especially those with small waist: hip ratio</article-title>. <source>J Hypertens</source> <volume>11</volume>: <fpage>1387</fpage>–<lpage>1394</lpage>.</citation>
</ref>
<ref id="bibr69-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nilsson</surname><given-names>P.M.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Sundquist</surname><given-names>J.</given-names></name>
<name><surname>Sundquist</surname><given-names>K.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Maternal cardiovascular disease risk in relation to the number of offspring born small for gestational age: national, multi-generational study of 2.7 million births</article-title>. <source>Acta Paediatrica</source> <volume>98</volume>: <fpage>985</fpage>–<lpage>989</lpage>.</citation>
</ref>
<ref id="bibr70-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nordby</surname><given-names>G.</given-names></name>
<name><surname>Os</surname><given-names>I.</given-names></name>
<name><surname>Kjeldsen</surname><given-names>S.E.</given-names></name>
<name><surname>Eide</surname><given-names>I.</given-names></name>
</person-group> (<year>1992</year>) <article-title>Mild essential hypertension in nonobese premenopausal women is characterized by low renin</article-title>. <source>Am J Hypertens</source> <volume>5</volume>: <fpage>579</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr71-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nuzzo</surname><given-names>A.</given-names></name>
<name><surname>Rossi</surname><given-names>R.</given-names></name>
<name><surname>Modena</surname><given-names>M.G.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Hypertension alone or related to the metabolic syndrome in postmenopausal women</article-title>. <source>Expert Rev Cardiovasc Ther</source> <volume>8</volume>: <fpage>1541</fpage>–<lpage>1548</lpage>.</citation>
</ref>
<ref id="bibr72-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Donnell</surname><given-names>C.J.</given-names></name>
<name><surname>Lindpaintner</surname><given-names>K.</given-names></name>
<name><surname>Larson</surname><given-names>M.G.</given-names></name>
<name><surname>Rao</surname><given-names>V.S.</given-names></name>
<name><surname>Ordovas</surname><given-names>J.M.</given-names></name>
<name><surname>Schaefer</surname><given-names>E.J.</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study</article-title>. <source>Circulation</source> <volume>97</volume>: <fpage>1766</fpage>–<lpage>1772</lpage>.</citation>
</ref>
<ref id="bibr73-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olsen</surname><given-names>H.</given-names></name>
<name><surname>Klemetsrud</surname><given-names>T.</given-names></name>
<name><surname>Stokke</surname><given-names>H.P.</given-names></name>
<name><surname>Tretli</surname><given-names>S.</given-names></name>
<name><surname>Westheim</surname><given-names>A.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway</article-title>. <source>Blood Press</source> <volume>8</volume>: <fpage>94</fpage>–<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr74-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oparil</surname><given-names>S.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Women and hypertension: what did we learn from the Women’s Health Initiative?</article-title> <source>Cardiol Rev</source> <volume>14</volume>: <fpage>267</fpage>–<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr75-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oparil</surname><given-names>S.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Hormone therapy of premature ovarian failure: the case for “natural” estrogen</article-title>. <source>Hypertension</source> <volume>53</volume>: <fpage>745</fpage>–<lpage>746</lpage>.</citation>
</ref>
<ref id="bibr76-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oparil</surname><given-names>S.</given-names></name>
<name><surname>Zaman</surname><given-names>M.A.</given-names></name>
<name><surname>Calhoun</surname><given-names>D.A.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Pathogenesis of hypertension</article-title>. <source>Ann Intern Med</source> <volume>139</volume>: <fpage>761</fpage>–<lpage>776</lpage>.</citation>
</ref>
<ref id="bibr77-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Os</surname><given-names>I.</given-names></name>
<name><surname>Bratland</surname><given-names>B.</given-names></name>
<name><surname>Dahlof</surname><given-names>B.</given-names></name>
<name><surname>Gisholt</surname><given-names>K.</given-names></name>
<name><surname>Syvertsen</surname><given-names>J.O.</given-names></name>
<name><surname>Tretli</surname><given-names>S.</given-names></name>
</person-group> (<year>1991</year>) <article-title>Lisinopril and nifedipine in essential hypertension: a Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients</article-title>. <source>J Hypertens Suppl</source> <volume>9</volume>(<issue>6</issue>): <fpage>S382</fpage>–<lpage>S383</lpage>.</citation>
</ref>
<ref id="bibr78-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Os</surname><given-names>I.</given-names></name>
<name><surname>Bratland</surname><given-names>B.</given-names></name>
<name><surname>Dahlof</surname><given-names>B.</given-names></name>
<name><surname>Gisholt</surname><given-names>K.</given-names></name>
<name><surname>Syvertsen</surname><given-names>J.O.</given-names></name>
<name><surname>Tretli</surname><given-names>S.</given-names></name>
</person-group> <year>1994</year>. <article-title>Female preponderance for lisinopril-induced cough in hypertension</article-title>. <source>Am J Hypertens</source> <volume>7</volume>: <fpage>1012</fpage>–<lpage>1015</lpage>.</citation>
</ref>
<ref id="bibr79-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Os</surname><given-names>I.</given-names></name>
<name><surname>Franco</surname><given-names>V.</given-names></name>
<name><surname>Kjeldsen</surname><given-names>S.E.</given-names></name>
<name><surname>Manhem</surname><given-names>K.</given-names></name>
<name><surname>Devereux</surname><given-names>R.B.</given-names></name>
<name><surname>Gerdts</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study</article-title>. <source>Hypertension</source> <volume>51</volume>: <fpage>1103</fpage>–<lpage>1108</lpage>.</citation>
</ref>
<ref id="bibr80-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Os</surname><given-names>I.</given-names></name>
<name><surname>Kjeldsen</surname><given-names>S.E.</given-names></name>
<name><surname>Nordby</surname><given-names>G.</given-names></name>
<name><surname>Eide</surname><given-names>I.</given-names></name>
<name><surname>Lande</surname><given-names>K.</given-names></name>
<name><surname>Hjermann</surname><given-names>I.</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Sex differences in essential hypertension</article-title>. <source>J Intern Med</source> <volume>233</volume>: <fpage>13</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr81-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Os</surname><given-names>I.</given-names></name>
<name><surname>Oparil</surname><given-names>S.</given-names></name>
<name><surname>Gerdts</surname><given-names>E.</given-names></name>
<name><surname>Hoieggen</surname><given-names>A.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Essential hypertension in women</article-title>. <source>Blood Press</source> <volume>13</volume>: <fpage>272</fpage>–<lpage>278</lpage>.</citation>
</ref>
<ref id="bibr82-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Psaty</surname><given-names>B.M.</given-names></name>
<name><surname>Smith</surname><given-names>N.L.</given-names></name>
<name><surname>Siscovick</surname><given-names>D.S.</given-names></name>
<name><surname>Koepsell</surname><given-names>T.D.</given-names></name>
<name><surname>Weiss</surname><given-names>N.S.</given-names></name>
<name><surname>Heckbert</surname><given-names>S.R.</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis</article-title>. <source>JAMA</source> <volume>277</volume>: <fpage>739</fpage>–<lpage>745</lpage>.</citation>
</ref>
<ref id="bibr83-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rahman</surname><given-names>M.</given-names></name>
<name><surname>Douglas</surname><given-names>J.G.</given-names></name>
<name><surname>Wright</surname><given-names>J.T.</given-names><suffix>Jr</suffix></name>
</person-group> (<year>1997</year>) <article-title>Pathophysiology and treatment implications of hypertension in the African-American population</article-title>. <source>Endocrinol Metab Clin North Am</source> <volume>26</volume>: <fpage>125</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr84-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rappelli</surname><given-names>A.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Hypertension and obesity after the menopause</article-title>. <source>J Hypertens Suppl</source> <volume>20</volume>(<issue>2</issue>): <fpage>S26</fpage>–<lpage>S28</lpage>.</citation>
</ref>
<ref id="bibr85-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reckelhoff</surname><given-names>J.F.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Gender differences in the regulation of blood pressure</article-title>. <source>Hypertension</source> <volume>37</volume>: <fpage>1199</fpage>–<lpage>1208</lpage>.</citation>
</ref>
<ref id="bibr86-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rich-Edwards</surname><given-names>J.W.</given-names></name>
<name><surname>Stampfer</surname><given-names>M.J.</given-names></name>
<name><surname>Manson</surname><given-names>J.E.</given-names></name>
<name><surname>Rosner</surname><given-names>B.</given-names></name>
<name><surname>Hankinson</surname><given-names>S.E.</given-names></name>
<name><surname>Colditz</surname><given-names>G.A.</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Birth weight and risk of cardiovascular disease in a cohort of women followed up since 1976</article-title>. <source>BMJ</source> <volume>315</volume>: <fpage>396</fpage>–<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr87-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roger</surname><given-names>V.L.</given-names></name>
<name><surname>Go</surname><given-names>A.S.</given-names></name>
<name><surname>Lloyd-Jones</surname><given-names>D.M.</given-names></name>
<name><surname>Adams</surname><given-names>R.J.</given-names></name>
<name><surname>Berry</surname><given-names>J.D.</given-names></name>
<name><surname>Brown</surname><given-names>T.M.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Heart disease and stroke statistics—2011 update: a report from the American Heart Association</article-title>. <source>Circulation</source> <volume>123</volume>: <fpage>e18</fpage>–<lpage>e209</lpage>.</citation>
</ref>
<ref id="bibr88-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Romundstad</surname><given-names>S.</given-names></name>
<name><surname>Holmen</surname><given-names>J.</given-names></name>
<name><surname>Hallan</surname><given-names>H.</given-names></name>
<name><surname>Kvenild</surname><given-names>K.</given-names></name>
<name><surname>Ellekjaer</surname><given-names>H.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter? The Nord-Trondelag Health Study (HUNT), Norway</article-title>. <source>Circulation</source> <volume>108</volume>: <fpage>2783</fpage>–<lpage>2789</lpage>.</citation>
</ref>
<ref id="bibr89-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ross</surname><given-names>A.E.</given-names></name>
<name><surname>Flaa</surname><given-names>A.</given-names></name>
<name><surname>Hoieggen</surname><given-names>A.</given-names></name>
<name><surname>Reims</surname><given-names>H.</given-names></name>
<name><surname>Eide</surname><given-names>I.K.</given-names></name>
<name><surname>Kjeldsen</surname><given-names>S.E.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Gender specific sympathetic and hemorrheological responses to mental stress in healthy young subjects</article-title>. <source>Scand Cardiovasc J</source> <volume>35</volume>: <fpage>307</fpage>–<lpage>312</lpage>.</citation>
</ref>
<ref id="bibr90-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossouw</surname><given-names>J.E.</given-names></name>
<name><surname>Anderson</surname><given-names>G.L.</given-names></name>
<name><surname>Prentice</surname><given-names>R.L.</given-names></name>
<name><surname>LaCroix</surname><given-names>A.Z.</given-names></name>
<name><surname>Kooperberg</surname><given-names>C.</given-names></name>
<name><surname>Stefanick</surname><given-names>M.L.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial</article-title>. <source>JAMA</source> <volume>288</volume>: <fpage>321</fpage>–<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr91-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sacks</surname><given-names>F.M.</given-names></name>
<name><surname>Svetkey</surname><given-names>L.P.</given-names></name>
<name><surname>Vollmer</surname><given-names>W.M.</given-names></name>
<name><surname>Appel</surname><given-names>L.J.</given-names></name>
<name><surname>Bray</surname><given-names>G.A.</given-names></name>
<name><surname>Harsha</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group</article-title>. <source>N Engl J Med</source> <volume>344</volume>: <fpage>3</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr92-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schunkert</surname><given-names>H.</given-names></name>
<name><surname>Danser</surname><given-names>A.H.</given-names></name>
<name><surname>Hense</surname><given-names>H.W.</given-names></name>
<name><surname>Derkx</surname><given-names>F.H.</given-names></name>
<name><surname>Kurzinger</surname><given-names>S.</given-names></name>
<name><surname>Riegger</surname><given-names>G.A.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women</article-title>. <source>Circulation</source> <volume>95</volume>: <fpage>39</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr93-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sethi</surname><given-names>A.A.</given-names></name>
<name><surname>Nordestgaard</surname><given-names>B.G.</given-names></name>
<name><surname>Gronholdt</surname><given-names>M.L.</given-names></name>
<name><surname>Steffensen</surname><given-names>R.</given-names></name>
<name><surname>Jensen</surname><given-names>G.</given-names></name>
<name><surname>Tybjaerg-Hansen</surname><given-names>A.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease</article-title>. <source>Hypertension</source> <volume>41</volume>: <fpage>1202</fpage>–<lpage>1211</lpage>.</citation>
</ref>
<ref id="bibr94-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sevre</surname><given-names>K.</given-names></name>
<name><surname>Lefrandt</surname><given-names>J.D.</given-names></name>
<name><surname>Nordby</surname><given-names>G.</given-names></name>
<name><surname>Os</surname><given-names>I.</given-names></name>
<name><surname>Mulder</surname><given-names>M.</given-names></name>
<name><surname>Gans</surname><given-names>R.O.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Autonomic function in hypertensive and normotensive subjects: the importance of gender</article-title>. <source>Hypertension</source> <volume>37</volume>: <fpage>1351</fpage>–<lpage>1356</lpage>.</citation>
</ref>
<ref id="bibr95-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname><given-names>J.P.</given-names></name>
<name><surname>Larson</surname><given-names>M.G.</given-names></name>
<name><surname>Tsuji</surname><given-names>H.</given-names></name>
<name><surname>Evans</surname><given-names>J.C.</given-names></name>
<name><surname>O’Donnell</surname><given-names>C.J.</given-names></name>
<name><surname>Levy</surname><given-names>D.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Reduced heart rate variability and new-onset hypertension: insights into pathogenesis of hypertension: the Framingham Heart Study</article-title>. <source>Hypertension</source> <volume>32</volume>: <fpage>293</fpage>–<lpage>297</lpage>.</citation>
</ref>
<ref id="bibr96-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>S.C.</given-names><suffix>Jr</suffix></name>
<name><surname>Allen</surname><given-names>J.</given-names></name>
<name><surname>Blair</surname><given-names>S.N.</given-names></name>
<name><surname>Bonow</surname><given-names>R.O.</given-names></name>
<name><surname>Brass</surname><given-names>L.M.</given-names></name>
<name><surname>Fonarow</surname><given-names>G.C.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute</article-title>. <source>Circulation</source> <volume>113</volume>: <fpage>2363</fpage>–<lpage>2372</lpage>.</citation>
</ref>
<ref id="bibr97-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tan</surname><given-names>Y.Y.</given-names></name>
<name><surname>Gast</surname><given-names>G.C.</given-names></name>
<name><surname>van der Schouw</surname><given-names>Y.T.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Gender differences in risk factors for coronary heart disease</article-title>. <source>Maturitas</source> <volume>65</volume>: <fpage>149</fpage>–<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr98-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vikse</surname><given-names>B.E.</given-names></name>
<name><surname>Irgens</surname><given-names>L.M.</given-names></name>
<name><surname>Leivestad</surname><given-names>T.</given-names></name>
<name><surname>Skjaerven</surname><given-names>R.</given-names></name>
<name><surname>Iversen</surname><given-names>B.M.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Preeclampsia and the risk of end-stage renal disease</article-title>. <source>N Engl J Med</source> <volume>359</volume>: <fpage>800</fpage>–<lpage>809</lpage>.</citation>
</ref>
<ref id="bibr99-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wallen</surname><given-names>W.J.</given-names></name>
<name><surname>Cserti</surname><given-names>C.</given-names></name>
<name><surname>Belanger</surname><given-names>M.P.</given-names></name>
<name><surname>Wittnich</surname><given-names>C.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Gender-differences in myocardial adaptation to afterload in normotensive and hypertensive rats</article-title>. <source>Hypertension</source> <volume>36</volume>: <fpage>774</fpage>–<lpage>779</lpage>.</citation>
</ref>
<ref id="bibr100-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wassertheil-Smoller</surname><given-names>S.</given-names></name>
<name><surname>Anderson</surname><given-names>G.</given-names></name>
<name><surname>Psaty</surname><given-names>B.M.</given-names></name>
<name><surname>Black</surname><given-names>H.R.</given-names></name>
<name><surname>Manson</surname><given-names>J.</given-names></name>
<name><surname>Wong</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Hypertension and its treatment in postmenopausal women: baseline data from the Women’s Health Initiative</article-title>. <source>Hypertension</source> <volume>36</volume>: <fpage>780</fpage>–<lpage>789</lpage>.</citation>
</ref>
<ref id="bibr101-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wassertheil-Smoller</surname><given-names>S.</given-names></name>
<name><surname>Blaufox</surname><given-names>M.D.</given-names></name>
<name><surname>Oberman</surname><given-names>A.</given-names></name>
<name><surname>Davis</surname><given-names>B.R.</given-names></name>
<name><surname>Swencionis</surname><given-names>C.</given-names></name>
<name><surname>Knerr</surname><given-names>M.O.</given-names></name><etal/>
</person-group>. (<year>1991</year>) <article-title>Effect of antihypertensives on sexual function and quality of life: the TAIM Study</article-title>. <source>Ann Intern Med</source> <volume>114</volume>: <fpage>613</fpage>–<lpage>620</lpage>.</citation>
</ref>
<ref id="bibr102-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilsgaard</surname><given-names>T.</given-names></name>
<name><surname>Schirmer</surname><given-names>H.</given-names></name>
<name><surname>Arnesen</surname><given-names>E.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Impact of body weight on blood pressure with a focus on sex differences: the Tromso Study, 1986–1995</article-title>. <source>Arch Intern Med</source> <volume>160</volume>: <fpage>2847</fpage>–<lpage>2853</lpage>.</citation>
</ref>
<ref id="bibr103-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>P.W.</given-names></name>
<name><surname>D’Agostino</surname><given-names>R.B.</given-names></name>
<name><surname>Sullivan</surname><given-names>L.</given-names></name>
<name><surname>Parise</surname><given-names>H.</given-names></name>
<name><surname>Kannel</surname><given-names>W.B.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Overweight and obesity as determinants of cardiovascular risk: the Framingham experience</article-title>. <source>Arch Intern Med</source> <volume>162</volume>: <fpage>1867</fpage>–<lpage>1872</lpage>.</citation>
</ref>
<ref id="bibr104-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wing</surname><given-names>L.M.</given-names></name>
<name><surname>Reid</surname><given-names>C.M.</given-names></name>
<name><surname>Ryan</surname><given-names>P.</given-names></name>
<name><surname>Beilin</surname><given-names>L.J.</given-names></name>
<name><surname>Brown</surname><given-names>M.A.</given-names></name>
<name><surname>Jennings</surname><given-names>G.L.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly</article-title>. <source>N Engl J Med</source> <volume>348</volume>: <fpage>583</fpage>–<lpage>592</lpage>.</citation>
</ref>
<ref id="bibr105-2040622312438935">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>X.P.</given-names></name>
<name><surname>Reckelhoff</surname><given-names>J.F.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Estrogen, hormonal replacement therapy and cardiovascular disease</article-title>. <source>Curr Opin Nephrol Hypertens</source> <volume>20</volume>: <fpage>133</fpage>–<lpage>138</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>